Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses

Fleeman, N; Dundar, Y; Dickson, R; Jorgensen, A; Pushpakom, S; McLeod, C; Pirmohamed, M; Walley, T
February 2011
Pharmacogenomics Journal;Feb2011, Vol. 11 Issue 1, p1
Academic Journal
There is wide variability in the response of individuals to standard doses of antipsychotic drugs. It has been suggested that this may be partly explained by differences in the cytochrome P450 (CYP450) enzyme system responsible for metabolizing the drugs. We conducted a systematic review and meta-analyses to consider whether testing for CYP450 single nucleotide polymorphisms in adults starting antipsychotic treatment for schizophrenia predicts and leads to improvements in clinical outcomes. High analytic validity in terms of sensitivity and specificity was seen in studies reporting P450 testing. However, there was limited evidence of the role of CYP2D6 polymorphisms in antipsychotic efficacy, although there was an association between CYP2D6 genotype and extrapyramidal adverse effects. No studies reported on the prospective use of CYP2D6 genotyping tests in clinical practice. In conclusion, evidence of clinical validity and utility of CYP2D6 testing in patients being prescribed antipsychotics is lacking, and thus, routine pharmacogenetic testing prior to antipsychotic prescription cannot be supported at present. Further research is required to improve the evidence base and to generate data on clinical validity and clinical utility.


Related Articles

  • Antipsychotic Trials in Schizophrenia from India: A Systematic Review and Meta-analysis. GROVER, S.; SARKAR, S. // Indian Journal of Pharmaceutical Sciences;Nov/Dec2015, Vol. 77 Issue 6, p771 

    Ethnic and regional variations have been found in the pharmacological treatment response. Though many efficacy studies have been conducted in India for antipsychotic treatment modalities of schizophrenia, there is a lack meta-analytic data of the existing literature from India. This study aimed...

  • Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis. Lindh, Jonatan D.; Holm, Lennart; Andersson, Marine L.; Rane, Anders // European Journal of Clinical Pharmacology;Apr2009, Vol. 65 Issue 4, p365 

    To quantify the influence of common cytochrome P450 2C9 ( CYP2C9) polymorphisms on warfarin dose requirements. A systematic review and a meta-analysis, calculating the warfarin dose reduction associated with the five most common variant CYP2C9 genotypes. Thirty-nine studies (7,907 patients) were...

  • Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis. Zhang, Jinhua; Tian, Lihong; Huang, Jinlong; Huang, Sihan; Chai, Tingting; Shen, Jianzhen // Cardiovascular Therapeutics;Feb2017, Vol. 35 Issue 1, p26 

    Aim To assess the effect of Cytochrome P450 2C9 ( CYP2C9) gene polymorphism on pediatric warfarin maintenance dosage requirement. Methods A previously developed search strategy was conducted in PubMed, EMBASE, and the Cochrane Library. Eligible studies published prior to January 27, 2016, were...

  • Challenges and Limitations in the Interpretation of Systematic Reviews: Making Sense of Clopidogrel and CYP2C19 Pharmacogenetics. Sorich, M J; Polasek, T M; Wiese, M D // Clinical Pharmacology & Therapeutics;Sep2013, Vol. 94 Issue 3, p376 

    From 2010 to 2012, nine systematic reviews reported highly variable conclusions regarding the association between carriage of a cytochrome P450 2C19 loss-of-function allele and the risk of adverse cardiovascular (CV) events in individuals using clopidogrel. Possible contributors to the variable...

  • A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics. Blake, C M; Kharasch, E D; Schwab, M; Nagele, P // Clinical Pharmacology & Therapeutics;Sep2013, Vol. 94 Issue 3, p394 

    Metoprolol, a commonly prescribed β-blocker, is primarily metabolized by cytochrome P450 2D6 (CYP2D6), an enzyme with substantial genetic heterogeneity. Several smaller studies have shown that metoprolol pharmacokinetics is influenced by CYP2D6 genotype and metabolizer phenotype. To increase...

  • Pharmacogenetics of Antipsychotics. Brandl, Eva J.; Kennedy, James L.; Müller, Daniel J. // Canadian Journal of Psychiatry;Feb2014, Vol. 59 Issue 2, p76 

    Objective: During the past decades, increasing efforts have been invested in studies to unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response, and occurrence of adverse effects. These studies aimed to improve clinical care by predicting outcome of treatment...

  • Interactions between the cytochrome P450 system and the second-generation antipsychotics. Prior, Trevor I.; Baker, Glen B. // Journal of Psychiatry & Neuroscience;Mar2003, Vol. 28 Issue 2, p99 

    Awareness of the metabolism of second-generation antipsychotics by the cytochrome P450 (CYP) system can inform the clinician about how to avoid and manage drug-drug interactions involving these enzymes. Clozapine is metabolized primarily by CYPIA2, with additional contributions by CYP2CI9,...

  • Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. Furukori, Hanako; Kondo, T.; Yasui, Norio; Otani, Koichi; Tokinaga, Noboru; Nagashima, Udai; Kaneko, Sunao; Inoue, Yoshimasa // Psychopharmacology;1999, Vol. 145 Issue 2, p189 

    Abstract Rationale: A previously reported pharmacokinetic interaction between bromperidol and carbamazepine, an inducer of cytochrome P450 (CYP) 3A4, suggests possible involvement of CYP3A4 in the metabolism of bromperidol. Objective: We investigated pharmacokinetic interaction between...

  • A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Caccia, Silvio; Invernizzi, Roberto William; Nobili, Alessandro; Pasina, Luca // Therapeutics & Clinical Risk Management;2013, Vol. 9, p319 

    Cariprazine is a potential antipsychotic awaiting approval from the US Food and Drug Administration. It is a dopamine D2- and D3-receptor partial agonist, with higher affinity for D3 receptors, as opposed to the D2 antagonism of most older antipsychotic agents. Like most lipophilic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics